MA31311B1 - Dérivés d'indazole substitués par oxadiazole, destinés à être utilisés comme agonistes de la sphingosine 1-phosphate (s1p) - Google Patents
Dérivés d'indazole substitués par oxadiazole, destinés à être utilisés comme agonistes de la sphingosine 1-phosphate (s1p)Info
- Publication number
- MA31311B1 MA31311B1 MA32280A MA32280A MA31311B1 MA 31311 B1 MA31311 B1 MA 31311B1 MA 32280 A MA32280 A MA 32280A MA 32280 A MA32280 A MA 32280A MA 31311 B1 MA31311 B1 MA 31311B1
- Authority
- MA
- Morocco
- Prior art keywords
- sphingosine
- agonists
- phosphate
- indazole derivatives
- substituted indazole
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
Abstract
La présente invention porte sur des composés de formule (i) ou des sels de ceux-ci, ayant une activité pharmacologique, sur des procédés pour leur préparation, sur des compositions pharmaceutiques les contenant, et sur leur utilisation dans le traitement de divers troubles liés aux récepteurs de s1p1.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0707617A GB0707617D0 (en) | 2007-04-19 | 2007-04-19 | Compounds |
GB0805993A GB0805993D0 (en) | 2008-04-02 | 2008-04-02 | Compounds |
PCT/EP2008/054647 WO2008128951A1 (fr) | 2007-04-19 | 2008-04-17 | Dérivés d'indazole substitués par oxadiazole, destinés à être utilisés comme agonistes de la sphingosine 1-phosphate (s1p) |
Publications (1)
Publication Number | Publication Date |
---|---|
MA31311B1 true MA31311B1 (fr) | 2010-04-01 |
Family
ID=39604751
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA32280A MA31311B1 (fr) | 2007-04-19 | 2009-10-15 | Dérivés d'indazole substitués par oxadiazole, destinés à être utilisés comme agonistes de la sphingosine 1-phosphate (s1p) |
Country Status (25)
Country | Link |
---|---|
US (1) | US8324254B2 (fr) |
EP (1) | EP2137181B1 (fr) |
JP (1) | JP5313229B2 (fr) |
KR (1) | KR20090130062A (fr) |
AR (1) | AR066095A1 (fr) |
AT (1) | ATE500252T1 (fr) |
AU (1) | AU2008240773B2 (fr) |
BR (1) | BRPI0809472A2 (fr) |
CA (1) | CA2684385A1 (fr) |
CL (1) | CL2008001099A1 (fr) |
CO (1) | CO6321136A2 (fr) |
CR (1) | CR11119A (fr) |
DE (1) | DE602008005285D1 (fr) |
DO (1) | DOP2009000237A (fr) |
EA (1) | EA016443B1 (fr) |
HK (1) | HK1138001A1 (fr) |
IL (1) | IL200870A (fr) |
JO (1) | JO2686B1 (fr) |
MA (1) | MA31311B1 (fr) |
MX (1) | MX2009011155A (fr) |
MY (1) | MY146606A (fr) |
NZ (1) | NZ579595A (fr) |
PE (1) | PE20090150A1 (fr) |
TW (1) | TWI408137B (fr) |
WO (1) | WO2008128951A1 (fr) |
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007116866A1 (fr) | 2006-04-03 | 2007-10-18 | Astellas Pharma Inc. | Compose hetero |
JO2701B1 (en) * | 2006-12-21 | 2013-03-03 | جلاكسو جروب ليميتد | Vehicles |
AU2008338965A1 (en) * | 2007-12-18 | 2009-06-25 | Arena Pharmaceuticals, Inc. | Tetrahydrocyclopenta[b]indol-3-yl carboxylic acid derivatives useful in the treatment of autoimmune and inflammatory disorders |
KR101247010B1 (ko) * | 2008-04-04 | 2013-03-26 | 일라이 릴리 앤드 캄파니 | 3-인다졸릴-4-피리딜이소티아졸 |
GB0807910D0 (en) * | 2008-04-30 | 2008-06-04 | Glaxo Group Ltd | Compounds |
KR20220084423A (ko) | 2008-07-23 | 2022-06-21 | 아레나 파마슈티칼스, 인크. | 자가면역성 및 염증성의 장애의 치료에 유용한 치환된 1,2,3,4-테트라히드로시클로펜타[b]인돌-3-일)아세트산 유도체 |
US9149459B2 (en) * | 2008-07-23 | 2015-10-06 | Novartis Ag | Sphingosine 1 phosphate receptor modulators and their use to treat muscle inflammation |
JP5731385B2 (ja) | 2008-08-22 | 2015-06-10 | バクスター・インターナショナル・インコーポレイテッドBaxter International Incorp0Rated | ポリマーベンジルカルボネート誘導体 |
SI2342205T1 (sl) | 2008-08-27 | 2016-09-30 | Arena Pharmaceuticals, Inc. | Substituirani triciklični kislinski derivati kot agonisti S1P1 receptorja, uporabni v zdravljenju avtoimunskih in vnetnih obolenj |
PE20110843A1 (es) | 2008-09-22 | 2011-12-08 | Cayman Chem Co | Derivados de 5-(1h-imidazol-5-il)-2-fenilpirimidina, como inhibidores de prostaglandina d sintasa hematopoyetica |
CA2743397C (fr) * | 2008-12-18 | 2017-02-28 | Mathilde Muzerelle | Derives heterocycliques fusionnes d'oxadiazole utiles pour le traitement de la sclerose en plaques |
GB0910691D0 (en) * | 2009-06-19 | 2009-08-05 | Glaxo Group Ltd | Novel compounds |
GB0910674D0 (en) | 2009-06-19 | 2009-08-05 | Glaxo Group Ltd | Novel compounds |
GB0910689D0 (en) * | 2009-06-19 | 2009-08-05 | Glaxo Wellcome Mfg Pte Ltd | Novel compounds |
US8399451B2 (en) * | 2009-08-07 | 2013-03-19 | Bristol-Myers Squibb Company | Heterocyclic compounds |
US20120283297A1 (en) * | 2009-12-18 | 2012-11-08 | Glaxo Wellcome House | Oxadiazole substituted indazole derivatives for use as sphingosine 1-phosphate 1 (s1p1) receptor agonists |
SG10201906876PA (en) | 2010-01-27 | 2019-09-27 | Arena Pharm Inc | Processes for the preparation of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid and salts thereof |
SG10201501575VA (en) | 2010-03-03 | 2015-04-29 | Arena Pharm Inc | Processes for the preparation of s1p1 receptor modulators and crystalline forms thereof |
JP6209541B2 (ja) | 2012-02-03 | 2017-10-04 | ノバルティス アーゲー | N−(4−シクロヘキシル−3−トリフルオロメチル−ベンジルオキシ)−アセトイミド酸エチルエステルの製造方法 |
JP2016028016A (ja) * | 2012-12-12 | 2016-02-25 | 大日本住友製薬株式会社 | オキサジアゾール誘導体とその医薬用途 |
CA2919980A1 (fr) * | 2013-08-20 | 2015-02-26 | Meiji Seika Pharma Co., Ltd. | Methode d'evaluation et methode de depistage de l'agoniste du recepteur s1p1 |
CN116850181A (zh) | 2015-01-06 | 2023-10-10 | 艾尼纳制药公司 | 治疗与s1p1受体有关的病症的方法 |
ES2929526T3 (es) | 2015-06-22 | 2022-11-29 | Arena Pharm Inc | Sal cristalina de L-arginina del ácido (R)-2-(7-(4-ciclopentil-3-(trifluorometil)benciloxi)-1,2,3,4-tetrahidrociclo-penta[b]indol-3-il)acético para su uso en trastornos asociados al receptor S1P1 |
CA3053416A1 (fr) | 2017-02-16 | 2018-08-23 | Arena Pharmaceuticals, Inc. | Composes et methodes pour le traitement de maladies inflammatoires chroniques de l'intestin avec manifestations extra-intestinales |
MA47504A (fr) | 2017-02-16 | 2019-12-25 | Arena Pharm Inc | Composés et méthodes de traitement de l'angiocholite biliaire primitive |
CN109100971B (zh) * | 2018-08-20 | 2024-02-09 | 合肥华耀电子工业有限公司 | 一种带互锁功能的开关机时序控制电路 |
KR20210074291A (ko) | 2018-09-06 | 2021-06-21 | 아레나 파마슈티칼스, 인크. | 자가면역 및 염증성 장애의 치료에 유용한 화합물 |
Family Cites Families (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3939238A1 (de) | 1989-11-28 | 1991-05-29 | Bayer Ag | Heterocyclisch substituierte acrylsaeureester |
US5462943A (en) * | 1990-01-28 | 1995-10-31 | Bayer Aktiengesellschaft | Substituted acetic acid esters useful as pesticides per se and as intermediates for substitued acrylic esters pesticides |
US5262416A (en) * | 1990-01-28 | 1993-11-16 | Bayer Aktiengesellschaft | Pesticidal substituted 2-[6-(pyrimidinyl)-indol-1-yl]-acrylic esters |
DE4002466A1 (de) | 1990-01-28 | 1991-10-10 | Bayer Ag | Substituierte 2-(6-(pyrimidinyl)-indo-l-yl)-acrylsaeureester |
US5523312A (en) * | 1994-09-27 | 1996-06-04 | Sterling Winthrop Inc. | Antipicornaviral agents |
JPH1180026A (ja) | 1997-09-02 | 1999-03-23 | Yoshitomi Pharmaceut Ind Ltd | 新規免疫抑制剤、その使用方法およびその同定方法 |
JP2001199983A (ja) * | 2000-01-18 | 2001-07-24 | Teijin Ltd | ベンズイミダゾール誘導体 |
WO2003105771A2 (fr) | 2002-06-17 | 2003-12-24 | Merck & Co., Inc. | 1-((5-aryl-1,2,4-oxadiazol-3-yl)benzyl)azetidine-3-carboxylates et 1-((5-aryl-1,2,4-oxadiazol-3-yl)benzyl)pyrrolidine-3-carboxylates utilises en tant qu'agonistes du recepteur edg |
JP4638410B2 (ja) * | 2003-04-30 | 2011-02-23 | ノバルティス アーゲー | スフィンゴシン−1−ホスフェートレセプターモジュレーターとしての、アミノプロパノール誘導体 |
US20060252741A1 (en) * | 2003-05-15 | 2006-11-09 | Colandrea Vincent J | 3-(2-amino-1-azacyclyl)-5-aryl-1,2,4-oxadiazoles as s1p receptor agonists |
CN1859908A (zh) * | 2003-10-01 | 2006-11-08 | 默克公司 | 作为s1p受体激动剂的3,5-芳基、杂芳基或环烷基取代的-1,2,4-噁二唑类化合物 |
CN1894225A (zh) * | 2003-12-17 | 2007-01-10 | 默克公司 | 作为鞘氨醇1-磷酸(内皮分化基因)受体激动剂的(3,4-二取代)丙酸酯 |
JP5315611B2 (ja) | 2004-06-23 | 2013-10-16 | 小野薬品工業株式会社 | S1p受容体結合能を有する化合物およびその用途 |
EP1804793A4 (fr) | 2004-10-22 | 2010-03-31 | Merck Sharp & Dohme | Carboxylates, sulfonates, phosphonates, phosphinates 2-(aryl)azacyclylmethyle et heterocycles utilises comme agonistes des recepteurs s1p |
RU2416601C2 (ru) * | 2005-02-25 | 2011-04-20 | Оно Фармасьютикал Ко., Лтд. | Соединение индола и его применение |
KR20070116645A (ko) | 2005-03-23 | 2007-12-10 | 액테리온 파마슈티칼 리미티드 | 스핑고신-1-포스페이트-1 수용체 길항제로서의 신규한티오펜 유도체 |
CN101203512A (zh) | 2005-04-22 | 2008-06-18 | 第一三共株式会社 | 杂环化合物 |
BRPI0612028A2 (pt) | 2005-06-08 | 2010-10-13 | Novartis Ag | oxadiazóis ou isodiazóis policìclicos e uso dos mesmos como ligantes de receptor s1p |
MX2008002540A (es) * | 2005-08-23 | 2008-03-14 | Irm Llc | Compuestos inmunosupresores y composiciones. |
GB0601744D0 (en) * | 2006-01-27 | 2006-03-08 | Novartis Ag | Organic compounds |
WO2007116866A1 (fr) * | 2006-04-03 | 2007-10-18 | Astellas Pharma Inc. | Compose hetero |
JO2701B1 (en) * | 2006-12-21 | 2013-03-03 | جلاكسو جروب ليميتد | Vehicles |
-
2008
- 2008-04-17 US US12/596,488 patent/US8324254B2/en not_active Expired - Fee Related
- 2008-04-17 EA EA200970967A patent/EA016443B1/ru not_active IP Right Cessation
- 2008-04-17 TW TW097113880A patent/TWI408137B/zh not_active IP Right Cessation
- 2008-04-17 MY MYPI20094368A patent/MY146606A/en unknown
- 2008-04-17 CA CA002684385A patent/CA2684385A1/fr not_active Abandoned
- 2008-04-17 AT AT08736315T patent/ATE500252T1/de not_active IP Right Cessation
- 2008-04-17 MX MX2009011155A patent/MX2009011155A/es active IP Right Grant
- 2008-04-17 BR BRPI0809472-1A patent/BRPI0809472A2/pt not_active IP Right Cessation
- 2008-04-17 AU AU2008240773A patent/AU2008240773B2/en not_active Expired - Fee Related
- 2008-04-17 DE DE602008005285T patent/DE602008005285D1/de active Active
- 2008-04-17 AR ARP080101584A patent/AR066095A1/es not_active Application Discontinuation
- 2008-04-17 PE PE2008000672A patent/PE20090150A1/es not_active Application Discontinuation
- 2008-04-17 EP EP08736315A patent/EP2137181B1/fr not_active Not-in-force
- 2008-04-17 CL CL200801099A patent/CL2008001099A1/es unknown
- 2008-04-17 JP JP2010503494A patent/JP5313229B2/ja not_active Expired - Fee Related
- 2008-04-17 JO JO2008183A patent/JO2686B1/en active
- 2008-04-17 WO PCT/EP2008/054647 patent/WO2008128951A1/fr active Application Filing
- 2008-04-17 KR KR1020097021613A patent/KR20090130062A/ko not_active Application Discontinuation
- 2008-04-17 NZ NZ579595A patent/NZ579595A/en not_active IP Right Cessation
-
2009
- 2009-09-10 IL IL200870A patent/IL200870A/en not_active IP Right Cessation
- 2009-10-08 DO DO2009000237A patent/DOP2009000237A/es unknown
- 2009-10-15 MA MA32280A patent/MA31311B1/fr unknown
- 2009-10-16 CO CO09115828A patent/CO6321136A2/es active IP Right Grant
- 2009-11-19 CR CR11119A patent/CR11119A/es not_active Application Discontinuation
-
2010
- 2010-04-29 HK HK10104250.5A patent/HK1138001A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
JP2010524886A (ja) | 2010-07-22 |
AU2008240773A1 (en) | 2008-10-30 |
EA016443B1 (ru) | 2012-05-30 |
CL2008001099A1 (es) | 2008-10-24 |
TW200911794A (en) | 2009-03-16 |
JP5313229B2 (ja) | 2013-10-09 |
TWI408137B (zh) | 2013-09-11 |
BRPI0809472A2 (pt) | 2014-09-09 |
US8324254B2 (en) | 2012-12-04 |
KR20090130062A (ko) | 2009-12-17 |
AU2008240773B2 (en) | 2013-10-03 |
DOP2009000237A (es) | 2010-05-31 |
PE20090150A1 (es) | 2009-05-08 |
NZ579595A (en) | 2012-06-29 |
US20100113528A1 (en) | 2010-05-06 |
CO6321136A2 (es) | 2011-09-20 |
MX2009011155A (es) | 2009-10-30 |
CR11119A (es) | 2010-01-18 |
AR066095A1 (es) | 2009-07-22 |
JO2686B1 (en) | 2013-03-03 |
WO2008128951A1 (fr) | 2008-10-30 |
EP2137181A1 (fr) | 2009-12-30 |
IL200870A0 (en) | 2010-05-17 |
MY146606A (en) | 2012-09-14 |
HK1138001A1 (en) | 2010-08-13 |
EA200970967A1 (ru) | 2010-02-26 |
IL200870A (en) | 2013-08-29 |
ATE500252T1 (de) | 2011-03-15 |
DE602008005285D1 (de) | 2011-04-14 |
CA2684385A1 (fr) | 2008-10-30 |
EP2137181B1 (fr) | 2011-03-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA31311B1 (fr) | Dérivés d'indazole substitués par oxadiazole, destinés à être utilisés comme agonistes de la sphingosine 1-phosphate (s1p) | |
MA31447B1 (fr) | Nouveaux dérivés d'acide dicarboxylique utilisés comme agonistes du récepteur s1p1 | |
KR101542812B1 (ko) | 당뇨병을 치료하기 위한 선택적인 안드로겐 수용체 모듈레이터 | |
MA30999B1 (fr) | Composés. | |
MA30232B1 (fr) | Inhibiteurs de kinase bases sur l'hydantoine | |
TN2009000112A1 (fr) | Derives de sulfonamides servant d'agonistes adrenergiques et d'antagonistes muscariniques | |
MA31419B1 (fr) | Derives de pyridine | |
MA29170B1 (fr) | Derives puriniques agissant comme des agonistes du recepteur a2a | |
TNSN07349A1 (fr) | Derives de n-(n-sulfonylaminomethyl) cyclopropanecarboxamide utiles pour le traitement de la douleur | |
TN2010000230A1 (fr) | Agonistes nouveaux des recepteurs de glucocorticoides | |
MA30696B1 (fr) | Derives de l'acide (3-amino-1,2,3,4-tetrahydro-9h-carbazol-9-yl)-acetique | |
MA27774A1 (fr) | Inhibiteurs de phosphatidylinositol 3-kinase | |
MA31087B1 (fr) | Derives d'amide et d'ester d'indazolyle pour traiter des troubles medies par le recepteur de glucocorticoïde. | |
MA30911B1 (fr) | Nouveaux derives de sulfonamide en tant qu'antagonistes de bradykinine | |
MA27779A1 (fr) | FORME CRISTALLINE D'AGONISTE DE RECEPTEUR β2 ADRENERGIQUE | |
MA30289B1 (fr) | Dérivés d'amines | |
MA29731B1 (fr) | Derives de pyridazinone utilises comme agonistes du recepteur de l'hormone tyroïdienne | |
MA32965B1 (fr) | Derives de sulfonamides | |
MA30084B1 (fr) | Triazolopyridazines en tant que modulateurs de la tyrosine kinase | |
MA31894B1 (fr) | Composes organiques | |
MA37866B1 (fr) | Dérivés de type aza-indazole ou diaza-indazole pour le traitement de la douleur | |
MA33604B1 (fr) | Composés et compositions en tant qu'inhibiteurs de protéine kinase | |
TN2009000138A1 (fr) | Biaryl-ether-urees | |
MA29839B1 (fr) | Derives de carboxamides servant d'antagonistes des recepteurs muscariniques | |
MA33533B1 (fr) | Compositions pharmaceutiques pour le traitement du cancer et d'autres maladies ou troubles |